Research programme: small molecule therapeutics - Novartis
Latest Information Update: 15 Feb 2024
At a glance
- Originator Novartis
- Developer Isomorphic Labs; Novartis
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified